Ondine Biomedical Inc.
OBI.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £43 | £29 | £65 | £185 |
| - Cash | £10 | £3 | £13 | £30 |
| + Debt | £0 | £1 | £1 | £1 |
| Enterprise Value | £34 | £27 | £53 | £155 |
| Revenue | £2 | £1 | £1 | £3 |
| % Growth | 70.3% | 88.6% | -75.2% | – |
| Gross Profit | £1 | £1 | £0 | £1 |
| % Margin | 64.5% | 58.4% | 45% | 48.8% |
| EBITDA | -£18 | -£14 | -£19 | -£48 |
| % Margin | -902.2% | -1,146.1% | -2,954.4% | -1,882.4% |
| Net Income | -£19 | -£14 | -£19 | -£50 |
| % Margin | -932.1% | -1,198% | -3,036.4% | -1,949.6% |
| EPS Diluted | -0.07 | -0.073 | -0.1 | -0.26 |
| % Growth | 4.2% | 26.9% | 61.5% | – |
| Operating Cash Flow | -£15 | -£14 | -£16 | -£13 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£16 | -£14 | -£17 | -£13 |